• Parkinsons is diagnosed through skilled observation of specialized neurologists
• Neurologist shortage could turn into public emergency
• EEGs may hold the key to clearer diagnosis of Parkinson’s

Every year an estimated 60,000 people in the United States are diagnosed with Parkinson’s disease (PD) (https://ibn.fm/ca0nb). Symptoms develop slowly, often spanning years, and vary from person to person. For a long time, PD has been diagnosed through the skilled observation of a neurologist, but recent studies suggest the EEG to be a promising diagnostic tool (https://ibn.fm/zCRAz). Brain Scientific (OTCQB: BRSF) is on a mission of modernizing brain diagnostics through cutting-edge technologies, which could have significant benefits for those experiencing and those not yet diagnosed with PD. With two FDA-cleared products — NeuroCap(TM) and NeuroEEG(TM) — BRSF is disrupting the EEG market by offering cost-effective, disposable solutions that have the ability to bridge the gap in access to neurological testing. In diagnosing PD, a movement disorder specialist, a neurologist specializing in PD, observes tasks performed by the patient to make a diagnosis. There is currently no exact method of diagnosis but rather a series of tests and tasks that occur over a period of time that lead to an educated conclusion (https://ibn.fm/5aUJM). There is an increase in need and a decrease in the number of those studying to become a neurologist, an estimated 19% shortage by 2025 (https://ibn.fm/to2MD). Access to care and availability of these much-needed appointments is decreasing. Take into account that a PD diagnosis is best made by a movement disorder specialist, and the gap increases even further. “You have very long wait times to see a neurologist, especially for chronic diseases like dementia, and you have huge shortages of specialists to treat people with stroke,” says Dr. Lee Schwamm, a Harvard Medical School neurology professor. Schwamm says the shortfall could turn into a public emergency if society doesn’t act soon. “We need to build capacity now, because it takes 10 years to train a neurologist,” he notes. The good news is that studies have found that EEGs may hold the key to a clearer diagnosis. According to a study published in eNeuro, the waveform shape that is detected with an EEG might be a biomarker for PD pathophysiology (https://ibn.fm/aRfro). A difference was found in PD patients who were on medication and those who were not. This provides the opportunity to diagnose PD and monitor the changes in the brain throughout the course of the disease, giving scientists more insight into how PD progresses. The challenge becomes making sure that those with symptoms have access to an EEG and a skilled neurologist for analysis. That’s where Brain Scientific’s FDA-cleared NeuroCap comes into play. The NeuroCap has clear advantages to its bulkier EEG counterpart. The bulkier version requires a skilled specialist to administer, comes with metal disks and wires, requires constant cleaning and sterilization, and takes up to 30 minutes to administer, not including prep or cleaning time. With the NeuroCap, any clinical personnel can apply the disposable headset in five minutes or less. This allows for EEGs to be administered in a almost any location, including the patient’s home or nursing homes, assisted living facilities or clinics. In addition, because the cap is disposable, there is no need to sanitize after each use; the device is also compatible with conventional EEG amplifiers. The data can be reviewed and evaluated through third-party software, reducing the need for a neurologist to be on site. Brain Scientific is making significant strides in its mission to bridge the widening gap in neurological care. PD diagnosis is only one of many neurological issues that the company is tackling. BRSF is working on algorithms to detect neurological disorders, including epilepsy, dementia and pre-Alzheimer’s diagnosis. For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Grapefruit USA Inc. holds licensing for manufacturing and distribution in California, issued in 2018; the company is positioned as a premier distributor and manufacturer in the state, with a focus on procuring, manufacturing and distributing the highest-quality materials
• With cannabis legalization gaining momentum worldwide, Grapefruit is currently uniquely situated to disrupt the market through its novel and proprietary products and services
• The global cannabis market is expected to grow to $97.35 billion by 2026, expanding at a CAGR of 32.92%
• The company provides a wealth of cannabis flower and cannabis products to licensed businesses, along with various services including distribution, manufacturing, toll processing, sourcing and more
• The company has effectively used science and technology to create patented, truly disruptive products for the recreational and medicinal marketplace
• Grapefruit’s patented Hourglass(TM) topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids
• Hourglass(TM) is manufactured exclusively at Grapefruit’s Coachillin facility by highly trained Grapefruit personnel and is available to the public only through Grapefruit authorized retailers; there is simply no other way possible for the public to obtain the benefits of the disruptive Hourglass experience
• Hourglass(TM) is a time-released topical cream that is available in full-spectrum and hemp-derived patented formulas
• The Hourglass(TM) topical delivery system features the Patchless Patch(TM) technology, providing a time-released full-spectrum entourage effect or a pure CBD experience
• Grapefruit will distribute the hemp-derived version of its Hourglass(TM) Topical Delivery Cream on a nationwide basis

Grapefruit USA (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products. The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses. Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products. Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace. Hourglass(TM) Topical Delivery Cream Grapefruit’s patented Hourglass(TM) topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids. Hourglass(TM) allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.* Hourglass(TM) is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal. Hourglass(TM) provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (“CBN”), Cannabigerol (“CBG”), Delta-8, Tetrahydrocannabivarin (“THCV”), and Cannabielsoin (“CBE”) in a Patchless Patch(TM) system that is novel and proprietary to the company. Hourglass(TM) Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass(TM) by Grapefruit. *This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease. Grapefruit Cannabis Services Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

• Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass(TM) topical delivery cream.
• Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass(TM) cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
• Hourglass(TM) Topical THC+CBD Delivery Cream – The company’s patented Hourglass(TM) Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass(TM) is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
• Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://ibn.fm/Fn3o4). Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology. Management Team Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility. Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations. For more information, visit the company’s website at www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Pure Extracts recently updated investors on successful completion of second tranche of its special warrants private placement
• In aggregate, Company will raise gross proceeds of $8.5 million through both tranches of private placement
• Pure Extracts will employ net proceeds from private placement towards capacity expansion for Company’s extraction business, and for general working capital purposes
• Company previously revealed that it was conducting study looking into formulation, manufacturing of psilocybin-based active treatments

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has recently updated investors following the successful completion of the second tranche of their non-brokered private placement offering of special warrants (https://ibn.fm/11Izm). Following the close of the second tranche, which resulted in Pure Extracts issuing an aggregate 10,839,230 special warrants for gross proceeds of $5,473,811.14, the company will have raised a total of $8,534,632.81 from its private placement.

The special warrants each comprised of one common share and one-half of a purchase warrant (with each warrant entitling the holder to acquire one common share at an exercise price of $0.65 per share for a period of 24 months following the deemed exercise date). The transaction is set to be completed upon the earlier of either a release of the final prospectus for the private placement or four months and a day from the closing date of the private placement, which is set to fall on May 21, 2021. All securities issued through the private placement will be subject to a four-month lock-up, expiring on May 21, 2021.

Pure Extracts will also pay finder’s fees of $139,501.41 cash and 395,817 finder’s warrants (with each finder’s warrant entitling the holder to purchase one common share of the Company at an exercise price of $0.65 per share, until January 20, 2023) as part of the private placement.

Pure Extracts has revealed that it is set to use the net proceeds from the private placement primarily for expansion of capacity for the Company’s extraction business and for general working capital purposes. The Company previously announced that it had recently embarked on a study looking into the formulation and manufacturing of psilocybin-based active treatments, which is being carried out under the auspices of the Toronto Institute of Pharmaceutical Technology.

In conjunction with the study, Pure Extracts recently revealed that the Company had begun construction on a fourth unit within its 10,000 square foot purpose-built facility, to be designated for its research and development into psilocybin and functional mushrooms as a whole (https://ibn.fm/Weggs).

The proceeds raised from the private placement will place Pure Extracts in a well-capitalized position to adequately finance the Company’s ongoing research into the functional and psychedelic mushrooms space while simultaneously building upon its ongoing extraction tolling business – a process through which the Company converts cannabis and hemp biomass into THC and CBD oil for both third parties and for its own-branded products.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• PacRoots Cannabis recently updated investors following its first successful hemp harvest, which resulted in 105,000 lbs. of biomass of higher-than-expected quality
• Canadian cannabis market is currently awash in oversupply, with some estimates placing inventory stockpile at close to 3 years’ worth of demand
• Industry participants have pointed at low-quality grades as prime cause for the oversupply
• PacRoots has taken strides to improve quality of its plants, most notably through collaboration with Phenome One Corp
• PacRoots processes, sells entirety of recent harvest to the Speakeasy Cannabis Club

PacRoots Cannabis (CSE: PACR) (OTCQB: PACRF), an up-and-coming cannabis company based out of Canada, has earned a well-established reputation for producing premium quality strains and products through the use of a meticulous, genetics-focused harvest approach. Following the award of an industrial hemp license by Health Canada in May 2020, PacRoots Cannabis embarked on a joint-venture with Rock Creek Farms to plant over 130,000 premium hemp CBD plants on 100 acres of prime arable land in British Columbia (https://ibn.fm/uNUYJ). The venture has been a notable success thus far, with the company recently revealing that the initial harvest had resulted in a biomass yield of over 105 thousand pounds—the quality of which far exceeded expectations. PacRoots’ success may soon be the industry exception rather than the rule. The Canadian cannabis market is increasingly awash with an excess supply of low-grade cannabis; Health Canada recently released industry-wide cannabis data for October 2020, which revealed that approximately 1.1 million kilograms of cannabis was being stockpiled by producers nationwide. According to industry thinktank Cannabis Benchmarks, the excess inventory—when taking into account that Canada’s monthly consumption rate—came to about 30,000 kilograms, effectively meaning that three years’ worth of supply was currently laying idle (https://ibn.fm/3FcCc). One key factor leading to the oversupply of cannabis may be the inferior quality of the product currently available. The recent harvest of outdoor cannabis pumped an additional 220,461 kilograms of legal marijuana into the market, which has led some cannabis retailers to re-evaluate their existing inventory. Tyler Robson, CEO of cannabis product manufacturer The Valens Co, said in an interview that the company was looking to scrap its inferior grade product now that it had better options for higher-quality material. “Commoditization is happening quicker than people expected,” he said. “I think this is at the inflection point of this space. And we wanted to get in front of it, prior to everybody else.” PacRoots has actively sought to improve the quality of its cannabis product, most recently through a strategic licensing agreement with Phenome One Corp. The agreement has granted PacRoots with access to one of Canada’s largest live, genetic cannabis libraries with lab and field-tested, selectively bred seedlings. The company has utilized these seedlings to grow, breed and clone its own unique brands. The tie-up in turn has allowed Pac Roots to offer customers a remarkable portfolio of over 350 meticulously-designed cultivars, ranging from CBD-dominant plants with rare terpene profiles to plants with over 30% THC-content as well as West Coast outdoor, botrytis-resistant cultivars. As a result, despite the current oversupply in the market, PacRoots Cannabis was able to process and sell its entire harvest to the Speakeasy Cannabis Club.  Furthermore, PacRoots also seized the opportunity to elaborate on its low-cost production capabilities, which the company believes will provide a decisive and sustainable competitive advantage relative to its peers while continuing to maintain healthy profit margins. The potent mix of a high-quality product and inexpensive production costs promise to place PacRoots Cannabis Corp in a decidedly advantageous position to benefit from the sector’s ongoing woes. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• The established and most prominent method of visualizing bladder cancer, white light, lacks the clarity needed to detect finer margins of tumors, which increases the likelihood of recurrence
• The more recent, improved method, blue light, provides clarity yet introduces cost barriers to adoption
• Imagin Medical’s i/Blue Imaging(TM) System combines the best of both methods, clarity and real-time visualization at a lower cost
• The system is highly adaptable to current endoscopic instruments, making it easy and affordable to implement

For over 30 years, the standard of visualizing bladder cancer during surgery has been white light illumination through an endoscopic procedure called a cystoscopy. When performing a cystoscopy, the surgeon uses the scope and white light to identify and remove the tumors that protrude above the bladder. Therein lies the problem, as the finer edges that need to be resected are not always clearly defined and tumors that lay flat against the bladder wall are often not visible using this technology. This inability to resect completely may contribute to the over 50% recurrence rate of bladder cancer.

While these limitations can be successfully overcome with the use of blue light and an imaging agent, this type of illumination has the drawback of not showing the cancer in real time. This requires surgeons to switch between white and blue light, making the procedure more challenging.

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on changing the standards of visualizing cancer during minimally invasive procedures, is intent on addressing these issues through its innovative technology that has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System eliminates the need to switch between the white and the blue light images by displaying both images side-by-side on a single screen.

The system is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. It therefore enables better visualization of tumors and margins, allowing for a more accurate resection.

The control unit is state-of-the-art, featuring a dual-wavelength light source, two-channel camera control unit, data recorder, and power supply. Simultaneous white and blue light illumination of the bladder allows for the side-to-side monitor images.

Additionally, Imagin Medical’s system is adaptable to most endoscopes already being used in hospitals. That means healthcare units that want to convert to the i/Blue Imaging(TM) System would not require new endoscopic equipment, resulting in cost savings.

The primary focus of Imagin Medical’s i/Blue Imaging(TM) System is bladder cancer, the sixth most prevalent type of cancer in the United States with one of the highest recurrence rates. The technology has the potential for use in other minimally invasive procedures, with plans already in motion to implement this system for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast dye agents and illumination sources.

Imagin Medical has made the transition from the development stage to manufacturing by contracting the services of Lighthouse Imaging, an FDA-registered and ISO 13485:2016-certified manufacturer, to accelerate production.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Agreement between RYAH, THC Lab outlines parameters for launch of RYAH’s IoT dose-measuring Smart-Inhaler
• Aim of agreement is to reach hundreds of pharmacies, establish RYAH as the market standard for vaporizing
• The two companies also planning to work together on controlled research, bioavailability testing projects

RYAH Group, a leading digital health care analytics and technology company, has entered into a research-and-distribution arrangement THC Lab, which specializes in providing products and services to compounding pharmacies in Italy and other European countries in the specific field of medical cannabis (https://ibn.fm/UPk8j). The agreement outlines the parameters for the launch of RYAH’s IoT dose-measuring Smart-Inhaler and data analytics platform in Italy and the Netherlands. “We are confident that together with RYAH we will be able to increase considerably the share of inhaled medical cannabis currently estimated at only 10% in Italy and around 20% in the Netherlands,” said THC Lab sales manager Andrea Ferrari. “Our aim is to reach out to hundreds of pharmacies and establish RYAH as the market standard for vaporizing. We are extremely excited about this new partnership and see tremendous synergies with our other commercial as well as scientific activities in the medical cannabis sector.” THC Lab appears to be an ideal partner for RYAH as the company expands globally. THC Lab has a vast network of compounding pharmacies, cannabis clinics and physicians, cannabis patient associations and pharmaceutical distributors. THC Lab will also support RYAH in further optimizing its Smart-Inhaler by providing patients the ability to provide invaluable feedback regarding the device through an integrated, in-app feedback forum. In addition to distribution arrangements, the two companies are planning to work together in a number of controlled research and bioavailability testing projects focused on studying the effectiveness of plant-based medicines in patients with various medical conditions. “We are thrilled by this cooperation as this gives us also the opportunity to contribute to the success and development of RYAH by providing our scientific input and carrying out joint observational studies on our patients,” said THC Lab CEO and technical director Dr. Annunziata Lombardi. A leading data and technology company, RYAH is pioneering the development of dose-measuring, plant-based delivery methods that capture vital consumption data. RYAH uses that essential data to create breakthrough discoveries aimed at advancing the validity of plant-based medicine and providing researchers with the tools needed to develop life-altering therapies. The company is developing a suite of IoT devices, including a dry-herb inhaler device paired with the software that is capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant-dose management. Its robust AI platform is created to aggregate and correlate HIPAA-compliant medical data intended to help doctors and patients personalize plant-based treatments to predict and obtain improved treatment outcomes. The essential data collected by the company can also be used by pharmacies, clinics, growers, dispensaries and Licensed Processors (“LPs”) to monitor and manage plant strain effects on patients. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities
• The company has research and development operations in North America and Europe and an operational focus in Germany
• XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual drug formulations, and psychedelic medicine
• The company’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system being evaluated in Europe for the detection of COVID-19
• XPhyto’s German subsidiary, Vektor Pharma TF GmbH, is advancing four therapeutic programs targeting neurological indications; the company intends to complete human pilot studies evaluating these products in 2021
• The company has two agreements in place focused on psychedelic compounds, a promising new class of API with strong potential for the treatment of mental health conditions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

• Commercialization of infectious disease diagnostics
• Clinical validation of transdermal and sublingual drug formulations
• Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (“CE-IVD”) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

• Rotigotine transdermal patch for Parkinson’s disease
• CBD oral/sublingual strip for treatment resistant epilepsy
• THC oral/sublingual strip for anorexia/nausea
• CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

• An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
• An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• BRSF paving way with next wave of innovation for neurology: e-tattoos
• Acceptance of telemedicine, AI here to stay following pandemic
• Scientists have learned how to read brain waves using minimally invasive, implantable, four-channel micro EEG to better monitor continuous seizures

The COVID-19 pandemic has accelerated several changes to American culture, many of which appear to be here to stay. According to Harvard experts, some of those changes include movement towards a cashless society, increased remote work, the decline of brick-and-mortar retail, and a new approach to health that includes an acceptance of telemedicine and artificial intelligence (“AI”) (https://ibn.fm/f9IJ5). Brain Scientific (OTCQB: BRSF) is positioned to benefit from that growing acceptance of AI as it focuses on modernizing brain diagnostics. Early in 2020, Elon Musk announced work on brain interface tech to turn humans into a genius super race. While Musk grabs the spotlight for all things high tech, his brain-computer chip company Neuralink went down as one of many overhyped AI ideas for the year (https://ibn.fm/E9mtr). Musk’s idea might sound like science fiction, allowing an external computer to input data as though the mind is nothing more than a computer processor, but the reverse is a reality. Elon Musk has dreams of fixing anything wrong with the brain, but before that can be achieved, the problem first needs to be identified and understood. Currently, scientists are working to understand what causes Parkinson’s disease, Alzheimer’s disease, dementia and other neurological issues. The root of the problem must be discovered before the solution is created. The good news is that BRSF is making inroads in helping identify those problems. The company has unveiled a new initiative to develop a brain E-Tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes would be connected to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. Each patient’s data is secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis. This provides 24/7 uninterrupted seizure monitoring, something that was unavailable previously with the bulky EEGs administered and overseen by specialized techs in hospitals. The EEG dates back to 1929 and has only seen drastic advances in the last few decades. “COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, co-founder and executive chairman at BRSF (https://ibn.fm/kP4jX). “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology. “The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions,” he continued. “Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life. While we aren’t yet ready as a society to cyborg our way past neurological issues, we are on the cusp of better understanding and diagnosing them. Thanks to cutting-edge technology like BRSF’s e-Tattoo, answers are right around the corner.” BRSF is committed to modernize brain diagnostics through cutting edge technologies that narrow the widening gap of accessibility to much needed neurological care. In addition to its e-tattoo innovation, the company has received FDA clearance for two transformative EEG products — the NeuroCap(TM) and NeuroEEG(TM) —  that have the potential to disrupt the market, provide EEG accessibility and 24/7 EEG coverage where it was once unavailable. For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Absorption vital component of product effectiveness
• CNSC’s proprietary CiBiDinol technology is cannabidiol made water compatible
• Xceptol products offer CBD in format more in line with body’s natural bioactivity

CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company marketing its exclusive Xceptol consumer brand. The company is the owner of Xceptor Labs, which uses proprietary technology to create Xceptol CBD products. The company complex has better absorption than currently marketed oil-based products — a key advantage when assessing products’ effectiveness. Drug absorption, or the way a drug is absorbed into the bloodstream, is a vital component in the effectiveness of treatments for a wide variety of diseases and disorders (https://ibn.fm/NlIT3). A product that claims some of the fastest rates on the market is worth paying attention to. Numerous factors can impact the absorption of a drug into the body, including solubility, drug formulation, administration route, and gastric emptying rate. These are all factors carefully evaluated by CannAssist, which utilizes its proprietary technology — CiBiDinol — in the formulation of its products and offering that technology to third-party providers. Developed by CannAssist founder Mark Palumbo and available through CNSC’s Xceptor Labs, CiBiDinol technology is cannabidiol made water compatible (https://ibn.fm/iHNsR). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms. The company’s innovative process combines CBD molecules with penetration-enhancing cyclodextrin, altering the CBD molecule’s surface and rendering it water dispersible. This technology improves absorption through the skin, mucosa and gut; it also enables administration through friendly dosage forms such as capsules, drops, creams and drinks. CannAssist notes that the technology provides CBD in a format that is more in line with the body’s natural bioactivity. Using this unique approach and exclusive technology as the basis for its entire product line, CannAssist offers an essential component for creating CBD products with more predictable potency. Xceptor Labs uses CiBiDinol in its CBD products, which have better absorption than currently marketed oil-based products. CannAssist launched its exclusive Xceptol product line in September 2020, which initially included its unscented pain cream formulated with CiBiDinol and ingredients with National Drug Codes registered with the FDA. The company has since added capsules and liquid drops to the product line, with plans for pet drops coming soon. CannAssist, the owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company. Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Gage opens its Grand Rapids, Michigan store — the company’s sixth provisioning center in the state
• Store offers more than 40 exclusive strains of flower in addition to variety of pre-rolls, edibles, concentrates, topicals, tinctures, CBD products and more
• Gage has single focus: to curate highest-quality cannabis experience possible for its consumers

Gage Cannabis kicked off 2021 with a bang — opening its sixth provisioning center (dispensary) in Michigan and the first in West Michigan (https://ibn.fm/Un9Rc). Gage Cannabis is a leading high-quality craft cannabis brand in Michigan.

“As a lifelong resident of Grand Rapids, I’m thrilled to introduce my hometown to Gage,” said Drew McCarthy, store manager and a local media personality. “While the company prides itself on the three Cs — cannabis, culture and community — in my short time with the company I’ve witnessed a fourth C, caring. I’m proud to be part of a company that cares about its employees, cares about its products and cares about the community.”

At this time, the 4,018-square-foot store is only open to medical marijuana cardholders, with orders available for curbside pick-up only. The store offers more than 40 exclusive strains of flower in addition to a variety of pre-rolls, edibles, concentrates, topicals, tinctures, CBD products, accessories and even apparel.

Gage has a single focus: to curate the highest-quality cannabis experience possible for its consumers (https://ibn.fm/mItNr). The company accomplishes this by growing its own plants in small batches using 100% hydroponic cultivation methods for sustainable and responsible operations. Every plant is handpicked, and then every plant undergoes Gage’s proprietary drying, trimming and curing process, with each step deliberately designed to deliver the best flower possible.

Gage selected Michigan to start its operations based on the state’s fast-growing legal cannabis market and consumer habits. In 2018, Michigan became the 10th state to legalize the recreational use of cannabis. In light of such favorable market dynamics, Gage opened its first medical provisioning center, or dispensary, in 2019. The company now has 13 medical or adult-use locations open or in the works, with an additional 10+ planned to open this year.

About Gage

Gage Cannabis Company is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the company’s founding partners have successfully built and grown operations with federal and state licenses including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries).

For more information, visit the company’s website at www.GageUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://ibn.fm/GAGE